

Lupus Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others), By Route of Administration (Oral, Intravenous, Subcutaneous), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, By Competition

https://marketpublishers.com/r/L10239E552A1EN.html

Date: October 2023

Pages: 180

Price: US\$ 4,900.00 (Single User License)

ID: L10239E552A1EN

Abstracts

Global Lupus Therapeutics Market is anticipated to witness formidable growth in the forecast period, 2024-2028. One of the key drivers of the global lupus therapeutics market is the increasing prevalence of the disease. The autoimmune disease lupus is brought on when the body's immune system attacks its own tissues and organs. Lupus-related inflammation can impact a variety of bodily functions, including joints, skin, kidneys, blood cells, brain, heart, and lungs. Because of how frequently its signs and symptoms resemble those of other illnesses, lupus can be challenging to diagnose. In many but not all cases of lupus, the most recognizable lupus symptom is a facial rash that looks like butterfly wings unfolding across both cheeks. Some people are predisposed to lupus from birth, which can be brought on by illnesses, medications, or even sunlight. According to Lupus Foundation of America, at least five million people worldwide have a form of lupus and the disease is more prevalent among the people belonging to age group 15-44.

Lupus has no known cure, but treatments can help manage symptoms. The market for lupus therapeutics is also being driven by advancements in technology and the development of new drugs. There are currently only a few FDA-approved drugs for the



treatment of lupus, but there are many promising drugs in the pipeline, propelling the growth of Global Lupus Therapeutics Market. In addition to traditional pharmaceuticals, there are also emerging therapies for lupus, such as gene therapy and stem cell therapy. These therapies have the potential to provide long-term relief from lupus symptoms and could be a game-changer in the treatment of the disease, leading to the expansion of Global Lupus Therapeutics Market. Apart from these, favorable government policies for developing Lupus Therapeutics and technological advancement for new applications propel the Global Lupus Therapeutics Market in the forecasted period. While there is currently no cure for lupus, several therapies are available to manage symptoms and prevent complications. The choice of therapy depends on the patient's symptoms, medical history, and other factors which are expected to grow Global Lupus Therapeutics Market.

Increasing Prevalence of Lupus propels the market growth for Lupus Therapeutics

The market for Lupus Therapeutics is anticipated to grow due to the rising cases of Lupus worldwide. The reasons behind the rising prevalence of lupus are not yet fully understood, but research has identified several potential factors. According to Lupus Foundation of America, 9 out of 10 adults who are suffering from lupus are women. One of the key factors is genetics. Studies have shown that certain genetic variations can increase the risk of developing lupus. For example, people with a specific variation in the gene known as IRF5 are more likely to develop lupus. However, genetics alone cannot explain the increasing prevalence of lupus. Environmental factors also play a significant role. Environmental factors such as pollution, toxins, and infectious agents have been linked to the development of lupus. Exposure to certain chemicals and pollutants, such as silica, has been shown to increase the risk of developing lupus, leading to the expansion of Global Lupus Therapeutics Market. Additionally, infections such as Epstein-Barr virus and cytomegalovirus have been linked to the onset of lupus. Changes in lifestyle and diet may also be contributing to the rising prevalence of lupus. According to a research article, "Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study", Systemic lupus erythematosus (SLE), is the most common type of lupus. The incidence of SLE in the general population varied from 1.18 (0.16 to 3.68) per 100?000 person-years in central Asia to 13.74 (3.2 to 31.82) per 100?000 person-years in central Europe. The top four countries with the highest estimates of SLE incidence were Poland followed by United States, Barbados, and China. A diet high in processed foods and low in nutrients can increase inflammation in the body, which can trigger autoimmune diseases such as lupus. Additionally, sedentary lifestyles and obesity have been linked to an increased risk of developing lupus, which is expected to expand Global Lupus Therapeutics



Market. According to the World Heart Federation, by 2025, 2.7 billion adults might be overweight or obese.

Rising Research and Development in Drug Discovery drives Global Lupus Therapeutics Market

Lupus is a complex disease that can affect various parts of the body, such as the skin, joints, kidneys, and lungs. While there are treatments available to manage the symptoms of lupus, there is no cure. Therefore, increasing research and development (R&D) efforts for lupus therapeutics is crucial to improve patient outcomes and quality of life and leading to the growth of Global Lupus Therapeutics Market. One of the main challenges in developing new therapeutics for lupus is the complex nature of the disease. Lupus is a multifactorial disease, meaning that there are many factors that contribute to its development and progression. These factors include genetic, environmental, and hormonal factors. Despite the challenges, there has been a growing interest in developing new therapeutics for lupus in recent years. One reason for this is the increasing understanding of the underlying mechanisms of the disease. Advances in genetic research and technology have allowed researchers to identify specific genes and pathways that are involved in the development and progression of lupus. This knowledge has led to the development of new drugs that can target these specific genes and pathways. Another reason for the increasing interest in lupus therapeutics is the growing demand for new treatments. While there are currently treatments available for lupus, they are not always effective for all patients, and many have significant side effects. Therefore, there is a need for new and improved therapies that can effectively manage the symptoms of lupus while minimizing side effects, hence augmenting the growth of Global Lupus Therapeutics Market. Collaboration between researchers and industry helps bridge the gap between basic research and clinical development and accelerate the development of new therapeutics. By working together, researchers leverage the expertise and resources of industry to develop new drugs and therapies leading to the huge demand for lupus therapeutics globally. In addition to funding and collaboration, there are also technological advancements that are leveraged to increase R&D efforts for lupus therapeutics. For example, advances in artificial intelligence and machine learning help to identify new drug targets and accelerate the drug discovery process. Similarly, advances in gene editing and gene therapy have helped in the development of more targeted and personalized therapies for lupus, which is expected to propel the growth of Global Lupus Therapeutics Market. As of 9th May 2023, as per clinicaltrials.gov, there are around 278 studies in different phases of development related to Lupus Therapeutics worldwide.



Mergers, Acquisitions and Collaborations

In June 2021, Progentec collaborated with GlaxoSmithKline, plc for an 18-month agreement to research new systemic lupus erythematosus (SLE or lupus) measurement and management tools.

In January 2023, EVOQ Therapeutics launched its collaboration and licensing agreement with Gilead Sciences to advance the latter's technology and create immunotherapies for the treatment of lupus. In accordance with the terms of the agreement, the two businesses will collaborate to advance the preclinical development of immunotherapies for RA and lupus.

Market Segmentation

Global Lupus Therapeutics Market is segmented based on Treatment Type, Route of Administration and End-User. Based on Treatment Type, the global lupus therapeutics market is divided into NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics and Others. Based on Route of Administration, the global lupus therapeutics market is divided into Oral, Intravenous and Subcutaneous. Based on End-User, the global lupus therapeutics market is divided into Hospitals & Clinics, Ambulatory Care Centers and Others.

Market players

GlaxoSmithKline, plc., Novartis AG, AstraZeneca, plc., Hoffmann-La Roche AG, Eli Lilly and Company. ImmuPharma PLC, Pfizer, Inc., Sanofi S.A., Bristl Myers Squibb Company, Merck & Co., Inc. are the key players operating in the global lupus therapeutics market.

Report Scope:


In this report, Global Lupus Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Lupus Therapeutics Market, By Treatment Type:

NSAIDs

Corticosteroids







Available Customizations:

Asia-Pacific		
C	China	
Ir	ndia	
J.	lapan	
А	Australia	
S	South Korea	
North America		
U	Jnited States	
C	Canada	
N	Mexico	
Middle East and Africa		
S	Saudi Arabia	
U	JAE	
S	South Africa	
Т	-urkey	
Competitive Landscape		
Company Profiles: Detailed analysis of the major companies present in Global Lupus Therapeutics Market.		

With the given market data, TechSci Research offers customizations according to a



company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).



Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. IMPACT OF COVID-19 ON GLOBAL LUPUS THERAPEUTICS MARKET

6. CLINICAL TRIAL ANALYSIS

- 6.1. Ongoing Clinical Trials
- 6.2. Completed Clinical Trials
- 6.3. Terminated Clinical Trials



- 6.4. Breakdown of Pipeline, By Development Phase
- 6.5. Breakdown of Pipeline, By Status
- 6.6. Breakdown of Pipeline, By Study Type
- 6.7. Breakdown of Pipeline, By Region
- 6.8. Clinical Trials Heat Map

7. GLOBAL LUPUS THERAPEUTICS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials,

Immunosuppressants, Biologics, Others)

- 7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
- 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 7.2.4. By Region
- 7.2.5. By Company (2022)
- 7.3. Market Map
 - 7.3.1. By Treatment Type
 - 7.3.2. By Route of Administration
 - 7.3.3. By End User
 - 7.3.4. By Region

8. NORTH AMERICA LUPUS THERAPEUTICS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Treatment Type
 - 8.2.2. By Route of Administration
 - 8.2.3. By End User
 - 8.2.4. By Country
- 8.3. North America: Country Analysis
 - 8.3.1. United States Lupus Therapeutics Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Treatment Type
 - 8.3.1.2.2. By Route of Administration



- 8.3.1.2.3. By End User
- 8.3.2. Canada Lupus Therapeutics Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Treatment Type
 - 8.3.2.2.2. By Route of Administration
 - 8.3.2.2.3. By End User
- 8.3.3. Mexico Lupus Therapeutics Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Treatment Type
 - 8.3.3.2.2. By Route of Administration
 - 8.3.3.2.3. By End User

9. EUROPE LUPUS THERAPEUTICS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Treatment Type
 - 9.2.2. By Route of Administration
 - 9.2.3. By End User
 - 9.2.4. By Country
- 9.3. Europe: Country Analysis
 - 9.3.1. Germany Lupus Therapeutics Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Treatment Type
 - 9.3.1.2.2. By Route of Administration
 - 9.3.1.2.3. By End User
 - 9.3.2. France Lupus Therapeutics Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Treatment Type
 - 9.3.2.2.2. By Route of Administration



- 9.3.2.2.3. By End User
- 9.3.3. United Kingdom Lupus Therapeutics Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Treatment Type
 - 9.3.3.2.2. By Route of Administration
 - 9.3.3.2.3. By End User
- 9.3.4. Spain Lupus Therapeutics Market Outlook
 - 9.3.4.1. Market Size & Forecast
 - 9.3.4.1.1. By Value
 - 9.3.4.2. Market Share & Forecast
 - 9.3.4.2.1. By Treatment Type
 - 9.3.4.2.2. By Route of Administration
 - 9.3.4.2.3. By End User
- 9.3.5. Italy Lupus Therapeutics Market Outlook
 - 9.3.5.1. Market Size & Forecast
 - 9.3.5.1.1. By Value
 - 9.3.5.2. Market Share & Forecast
 - 9.3.5.2.1. By Treatment Type
 - 9.3.5.2.2. By Route of Administration
 - 9.3.5.2.3. By End User

10. ASIA-PACIFIC LUPUS THERAPEUTICS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Treatment Type
 - 10.2.2. By Route of Administration
 - 10.2.3. By End User
 - 10.2.4. By Country
- 10.3. Asia-Pacific: Country Analysis
 - 10.3.1. China Lupus Therapeutics Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Treatment Type
 - 10.3.1.2.2. By Route of Administration



10.3.1.2.3. By End User

10.3.2. India Lupus Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Treatment Type

10.3.2.2.2. By Route of Administration

10.3.2.2.3. By End User

10.3.3. Japan Lupus Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Treatment Type

10.3.3.2.2. By Route of Administration

10.3.3.2.3. By End User

10.3.4. South Korea Lupus Therapeutics Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Treatment Type

10.3.4.2.2. By Route of Administration

10.3.4.2.3. By End User

10.3.5. Australia Lupus Therapeutics Market Outlook

10.3.5.1. Market Size & Forecast

10.3.5.1.1. By Value

10.3.5.2. Market Share & Forecast

10.3.5.2.1. By Treatment Type

10.3.5.2.2. By Route of Administration

10.3.5.2.3. By End User

11. SOUTH AMERICA LUPUS THERAPEUTICS MARKET OUTLOOK

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Treatment Type

11.2.2. By Route of Administration

11.2.3. By End User

11.2.4. By Country



- 11.3. South America: Country Analysis
 - 11.3.1. Brazil Lupus Therapeutics Market Outlook
 - 11.3.1.1. Market Size & Forecast
 - 11.3.1.1.1 By Value
 - 11.3.1.2. Market Share & Forecast
 - 11.3.1.2.1. By Treatment Type
 - 11.3.1.2.2. By Route of Administration
 - 11.3.1.2.3. By End User
 - 11.3.2. Argentina Lupus Therapeutics Market Outlook
 - 11.3.2.1. Market Size & Forecast
 - 11.3.2.1.1. By Value
 - 11.3.2.2. Market Share & Forecast
 - 11.3.2.2.1. By Treatment Type
 - 11.3.2.2.2. By Route of Administration
 - 11.3.2.2.3. By End User
 - 11.3.3. Colombia Lupus Therapeutics Market Outlook
 - 11.3.3.1. Market Size & Forecast
 - 11.3.3.1.1. By Value
 - 11.3.3.2. Market Share & Forecast
 - 11.3.3.2.1. By Treatment Type
 - 11.3.3.2.2. By Route of Administration
 - 11.3.3.2.3. By End User

12. MIDDLE EAST AND AFRICA LUPUS THERAPEUTICS MARKET OUTLOOK

- 12.1. Market Size & Forecast
 - 12.1.1. By Value
- 12.2. Market Share & Forecast
 - 12.2.1. By Treatment Type
 - 12.2.2. By Route of Administration
 - 12.2.3. By End User
 - 12.2.4. By Country
- 12.3. MEA: Country Analysis
- 12.3.1. South Africa Lupus Therapeutics Market Outlook
 - 12.3.1.1. Market Size & Forecast
 - 12.3.1.1.1. By Value
 - 12.3.1.2. Market Share & Forecast
 - 12.3.1.2.1. By Treatment Type
 - 12.3.1.2.2. By Route of Administration



12.3.1.2.3. By End User

12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook

12.3.2.1. Market Size & Forecast

12.3.2.1.1. By Value

12.3.2.2. Market Share & Forecast

12.3.2.2.1. By Treatment Type

12.3.2.2.2. By Route of Administration

12.3.2.2.3. By End User

12.3.3. UAE Lupus Therapeutics Market Outlook

12.3.3.1. Market Size & Forecast

12.3.3.1.1. By Value

12.3.3.2. Market Share & Forecast

12.3.3.2.1. By Treatment Type

12.3.3.2.2. By Route of Administration

12.3.3.2.3. By End User

12.3.4. Turkey Lupus Therapeutics Market Outlook

12.3.4.1. Market Size & Forecast

12.3.4.1.1. By Value

12.3.4.2. Market Share & Forecast

12.3.4.2.1. By Treatment Type

12.3.4.2.2. By Route of Administration

12.3.4.2.3. By End User

13. MARKET DYNAMICS

13.1. Drivers

13.2. Challenges

14. MARKET TRENDS & DEVELOPMENTS

14.1. Product Launches

14.2. Mergers & Acquisitions

14.3. Recent Developments

15. GLOBAL LUPUS THERAPEUTICS MARKET: SWOT ANALYSIS

16. PORTER'S FIVE FORCES ANALYSIS



- 16.1. Competition in the Industry
- 16.2. Potential of New Entrants
- 16.3. Power of Suppliers
- 16.4. Power of Customers
- 16.5. Threat of Substitute Products

17. COMPETITIVE LANDSCAPE

- 17.1. Business Overview
- 17.2. Company Snapshot
- 17.3. Products & Services
- 17.4. Financials (In case of listed companies)
- 17.5. Recent Developments
- 17.6. SWOT Analysis
 - 17.6.1. GlaxoSmithKline, plc.
 - 17.6.2. Novartis AG
 - 17.6.3. AstraZeneca, plc.
 - 17.6.4. F. Hoffmann-La Roche AG
 - 17.6.5. Eli Lilly and Company
 - 17.6.6. ImmuPharma PLC
 - 17.6.7. Pfizer, Inc.
 - 17.6.8. Sanofi S.A.
 - 17.6.9. Bristl Myers Squibb Company
 - 17.6.10. Merck & Co., Inc.

18. STRATEGIC RECOMMENDATIONS

19. ABOUT US & DISCLAIMER



I would like to order

Product name: Lupus Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and

Forecast, 2018-2028 Segmented By Treatment Type (NSAIDs, Corticosteroids,

Antimalarials, Immunosuppressants, Biologics, Others), By Route of Administration (Oral, Intravenous, Subcutaneous), By End User (Hospitals & Clinics, Ambulatory Care Centers,

Others), By Region, By Competition

Product link: https://marketpublishers.com/r/L10239E552A1EN.html

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/L10239E552A1EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$